What was a key outcome of the EMN19 trial in extramedullary multiple myeloma?
Low response rates with short progression-free survival
MRD negativity alone without impact on survival
100% progression-free survival with combined MRD negativity and metabolic response
No correlation between tumour burden and outcomes